AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Rapid7, Inc.
Video analysis: RPD
All videosNo video analysis for this stock yet. Request one from our team.
News: RPD
Hsbc Holdings PLC Purchases 86,623 Shares of Rapid7, Inc. $RPD
Hsbc Holdings PLC boosted its position in Rapid7, Inc. (NASDAQ: RPD) by 252.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,946 shares of the technology company's stock after purchasing an additional 86,623 shares during the period.
Rapid7, Inc. (RPD) Presents at Citi's 2026 Global TMT Conference Transcript
Rapid7, Inc. (RPD) Presents at Citi's 2026 Global TMT Conference Transcript
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and Europe There are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV) Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and Europe There are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Rapid7 to Participate in Upcoming Investor Conferences
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, today announced that the company will be attending the following conferences:
Rapid7 Inc (RPD) Shares Fall 7.8% -- What GF Score of 54 Tells Investors
On September 02, 2026, Rapid7 Inc (RPD) shares fell 7.8% to $11.07, marking a significant decline in an already challenging year. The stock has fluctuated betwe
Rapid7: Q2 Beat Validates The Bull Case
Rapid7 remains a 'Buy,' considering the positive read-throughs from its recent quarterly disclosures. RPD's 2Q2026 EPS came in 26% above consensus, as the EBIT margin expanded sequentially by 200bps to 13.7%. The second-quarter beat aligns with my belief that RPD is benefiting from AI-linked demand and cost-cutting under new leadership.
Rapid7 Finds Nearly Two-Thirds of Vulnerabilities Exploited in Q2 2026 Required No User Interaction to Initiate
BOSTON, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, today released its Quarterly Threat Landscape Report , revealing that rising vulnerability volumes and faster weaponization are breaking traditional patching models. The findings reinforce that security teams must move beyond static severity scores and prioritize the exposures attackers can realistically exploit.
